OncoVista Innovative Therapies, Inc.
OVIT
$0.0001
-$0.0001-50.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 320.27% | 352.84% | 238.13% | 201.87% | -2.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.96% | 157.72% | 87.45% | 67.26% | -18.24% |
| Operating Income | -170.96% | -157.72% | -87.45% | -67.26% | 18.24% |
| Income Before Tax | -142.45% | -39.76% | -92.12% | -75.52% | 5.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -142.45% | -39.76% | -92.12% | -75.52% | 5.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.45% | -39.76% | -92.12% | -75.52% | 5.28% |
| EBIT | -170.96% | -157.72% | -87.45% | -67.26% | 18.24% |
| EBITDA | -171.03% | -157.94% | -87.74% | -67.55% | 18.03% |
| EPS Basic | -138.46% | -38.15% | -91.24% | -75.07% | 5.17% |
| Normalized Basic EPS | -139.07% | -38.08% | -91.27% | -74.94% | 5.58% |
| EPS Diluted | -138.46% | -38.15% | -91.24% | -75.07% | 5.17% |
| Normalized Diluted EPS | -139.07% | -38.08% | -91.27% | -74.94% | 5.58% |
| Average Basic Shares Outstanding | 2.65% | 1.00% | 0.55% | 0.11% | 0.00% |
| Average Diluted Shares Outstanding | 2.65% | 1.00% | 0.55% | 0.11% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |